News

Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025

Lead development candidate, AMP-410, is activated only by VEGF signals in tumors and binds to the 4-1BB receptor on immune cells to drive immune response and anti-tumor activity

Ampersand Biomedicines Raises Series B Financing and Highlights Pipeline Advancements

$65 million in Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & Company; Two lead programs in immuno-inflammation and immuno-oncology planned to enter IND-enabling studies in 2025; Second discovery partnership in obesity initiated

Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

Ampersand’s AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets; Montai’s CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target; Collaborations will leverage Pfizer’s deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company

Ampersand Biomedicines Acquires AbCheck to Accelerate Platform and Product Development

Acquisition amplifies Ampersand’s in-house capabilities to generate AND-Body™ Therapeutics - programmed biologics across a broad range of diseases

Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

Gardner brings more than two decades of leadership experience across pharmaceutical and biotechnology companies, with deep expertise in drug discovery and development, and a successful track record of securing strategic partnerships, scaling companies, and building teams.

Ampersand Biomedicines set to develop programmable, more targeted therapeutics

Flagship Pioneering Inc. has unveiled Ampersand Biomedicines, a company creating programmable medicines that are safer, more tolerable and effective by acting at the site of disease.

Flagship’s latest startup aims to develop drugs with fewer side effects

Ampersand Biomedicines launches with $50 million from the Cambridge firm to design medicines that better target the site of a disease than existing treatments.

Flagship spins out $50M precision medicine startup

Flagship Pioneering is unveiling a new startup that takes aim at tricky-to-drug bodily targets by creating an "address map" of the human body.

Flagship unveils latest brainchild: Ampersand Biomedicines

Flagship Pioneering has revealed yet another pharmaceutical start-up—Ampersand Biomedicines. With $50 million in funding, the newly launched company aims to design programmable, tissue-selective medicines.

Ampersand snags $50M as Flagship focuses therapeutics on desired targets only

The behemoth biotech creator Flagship Pioneering is out with another startup aiming to achieve the crown jewel of drug development: treatments that hit only the desired target and cause no unwanted effects elsewhere.

Flagship’s latest startup emerges with a plan for ‘smarter biologics’

Ampersand Biomedicines, a biotechnology startup focusing on what it calls programmable medicines, is emerging from stealth with $50 million in hand from Flagship Pioneering.

Flagship fledging fetches $50M to fire drugs at specific organs, fix on-target, off-tissue toxicity

Flagship Pioneering is back with a new biotech designed to tackle a key drug development challenge: on-target, off-tissue toxicity.

Flagship Pioneering Unveils Ampersand Biomedicines to Create Highly Effective Medicines That are Programed to Act Only Where Needed

The company's proprietary Address, Navigate, Design (AND)™ Platform produces medicines that are better, safer and more tolerable for patients. After two years of development, Flagship commits $50 million to advance the company's platform and build an initial pipeline of therapeutics.

Flagship Startup Emerges With $50M to Send Drugs to the Right Biologic Address

Ampersand Biomedicines emerged from stealth with technology for site-specific drug delivery that avoids toxic effects throughout the body. The Flagship Pioneering-founded startup is backed by $50 million in financing.

Ampersand, Rapport launches reflect precision medicine trend

Ampersand Biomedicines, the latest company to emerge from Flagship Pioneering, is using its $50 million of funding to develop a platform for creating modular therapeutics that are localized to specific target tissues.